An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS)

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 6, 2008, Pages 1073-1087

  Harguindey, Salvador ^a   Orive, Gorka ^b,f   Cacabelos, Ramón ^c   Hevia, Enrique Meléndez ^d   de Otazu, Ramón Díaz ^e   Arranz, Jose Luis ^a   Anitua, Eduardo ^f  

^a Institute of Clinical Biology and Metabolism   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Centro de Investigacion Biomedica EuroEspes   (Spain)

^d Institute for Cellular Metabolism   (Spain)

^e HOSPITAL TXAGORRITXU   (Spain)

^f BTI Biotechnology Institute   (Spain)

Author keywords

Alzheimer's Disease; Antiapoptosis; Apoptosis; Cancer; Etiopathogenesis and treatment; Human neurodegenerative diseases; Intracellular acid base homeostasis; Neurodegenerative diseases and growth factors

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; MULTIDRUG RESISTANCE PROTEIN; NEUROTROPHIC FACTOR; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; SOMATOMEDIN; VASCULOTROPIN;

ALZHEIMER DISEASE; APOPTOSIS; CANCER INVASION; CELL DEATH; CELL FUNCTION; CELL METABOLISM; CELL PH; CELL SPECIFICITY; CELL TRANSFORMATION; DEGENERATIVE DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PROTON SODIUM EXCHANGE; REVIEW; SIGNAL TRANSDUCTION;

EID: 60249095085     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3800     Document Type: Review

References (160)

1. Alio JL, Colecha JR, Pastor S, et al. 2007. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res, 39:124-9.
2. Anitua E, Andia I, Ardanza B, et al. 2004. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost, 9:4-15.
3. Anitua E, Andia I, Sanchez M, et al. 2005. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res, 23:281-6.
4. Anitua E, Sanchez M, Nurden AT, et al. 2006. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res, 77:285-93.
5. Anitua E, Sanchez M, Nurden AT, et al. 2007a. Reciprocal actions of platelet-secreted TGF-β1 on the production of VEGF and HGF by human tendon cells. Plastic Reconstruct Surg, 119:950-9.
6. Anitua E, Sánchez M, Orive G, Andía I. 2007b. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials, 28:4551-60.
7. Anitua, E. Aguirre JJ, Algorta J, et al. 2008a. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B, 84:415-21.
8. Anitua E, Sánchez M, Orive G, et al. 2008b. Delivering growth factors for therapeutics. Trends Pharmacol Sci, 29:37-41.
9. Alvarez A, Cacabelos R, Sanpedro C, et al. 2007. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging, 28:533-6.
10. Appel SH. 1983. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, Parkinsonism and Alzehimer's disease. 1981. Ann Neurol, 10:499-505.
11. Araki W, Wurtman RJ. 1998. Increased expression of amyloid precursor protein and amyloid precursor-like protein 2 during trophic factor withdrawal-induced death of neuronal PC12 cells. Mol Brain Res, 56:169-77.
12. Arianna V, Laura N, Cinzia M, et al. 2007. Modification of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites. Neurobiol Aging, 28:987-94.
13. Barbin G. 1987. Le viellissement cerebral normal and pathologique. In: Maloine SA (ed). Colloques de la Fondation Nationale de Gerontologie. p.114-23.
14. Belaud-Rotureau MA, Leducq N, de Gannes FMP. 2000. Early transitory rise in intracellular pH leads to Bax conformation change during ceramide-induced apoptosis. Apoptosis, 5:551-60.
15. Bialek M, Zaremba P, Borowicz KK, et al. 2004. Neuroprotective role of testosterone in the nervous system. 2004. Polish J Pharmacol, 56:509-18.
16. Bredesen DE, Rao RV, Mehlen P. 2006. Cell death in the nervous system. Nature, 443:796-802.
17. Brodski C, Vogt Weisenhorn MV, Dechant G. 2002. Therapy of neurodegenerative diseases using neurotrophic factors: cell biological perspective. Expert Rev Neurotherapeutics, 2:89-98.
18. Bröker LE, Kruyt FAE, Giaccone G. 2005. Cell death independent of caspases: a review. Clin Cancer Res, 11:3155-62.
19. Burns CP, Rozengurt E. 1983. Serum, Platelet-derived growth factor, vasopressin and phorbol esters increase intracellular pH in swiss 3T3 cells. Biochem Biophs Res Comm, 116:931-8.
20. Cacabelos R. 2005. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease. Aging Health, 1:303-48.
21. Cacabelos R, Takeda M. 2006. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future, 31 (Suppl B):5-146.
22. Cao L, Jiao X, Zuzga DS, et al. 2004. VEGF links hippocampal activity with neurogenesis, learning and memory. Nature Genetics, 36:827-35.
23. + exchanger in metastasis. Nature Revs Cancer, 5:786-95.
24. Consolo U, Zaffe D, Bertoldi C, et al. 2007. Platelet-rich plasma activity on maxillary sinus floor augmentation by autologous bone. Clin Oral Implants Res, 18:252-62.
25. Corzo L, Zas R, Rodríguez, et al. 2007. Decreased levels of serum nitric oxide in different forms of dementia. Neurosci Lett, 420:263-7.
26. Counts SE, Mufson EJ. 2005. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol, 64:263-72.
27. Chao MV, Rajagopal R, Lee FS. 2006. Neurothropin signalling in health and disease. Clin Sci, 110:167-73.
28. Chan SL, Tammariello SP, Estus S, et al. 1999. Prostate apoptosis response-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurones: actions prior to mitochondrial dysfunction and caspase activity. J Neurochem, 73:502-12.
29. Choi B-M, Pae H-O, Jang SII et al. 2002. Nitric oxide as pro-apoptotic as well as anti-apoptotic modulator. J Biochem Mol Biol, 35:116-26.
30. Dass B, Warren Olanov C, Kordover JH. 2006. Gene transfer of trophic factors and stem cells grafting as treatments for Parkinson's disease. Neurology, 66:S89-S103.
31. Del Bo R, Scarlato M, Ghezzi S, et al. 2005. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol, 57:373-80.
32. Deshmukh M, Johnson EM. 1997. Programmed cell death in neurons: focus on the pathway of nerve growth factor deprivation-induced death of sympathetic neurones. Mol Pharmacol, 51:897-906.
33. Deshmukh M, Kuida K, Johnson EM. 2000. Caspase inhibition extends the commitment to neural death beyond cytochrome C release to the point of mitochondrial depolarization. J Cell Biol, 150:131-43.
34. DiGiammarino J, Lee ADS, Cadwell C, et al. 2000. A novel mechanism of tumorogenesis involving pH-dependent desestabilization of a mutant p53 tetramer. Nature Struct Biol, 9:12-16.
35. + exchange activity in human hepatic stellate cells: effect of platelet-derived growth factor, insulin-like growth factor 1 and insulin, J Hepatology, 34:378-85.
36. Di Sario A, Bendia E, Omenetti A, et al. 2007. Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptosis in cholangiocarcinoma cells. Digestive Liver Dis, 39:60-9.
37. Ebert AD, Svendsen CN. 2005. A new tool in the battle against Alzheimer's disease and aging: ex vivo gene therapy. Rejuvenation Res, 8:131-4.
38. Estévez AG, Sampson JB, Zhuang YX, et al. 2000. Liposome-derived superoxide dismutase prevents nitric oxide-dependent motor neuron death induced by trophic factor withdrawal. Free Rad Biol Med, 28:437-46.
39. Estévez A, Jordán J. 2002. Nitric acid and superoxide, a deadly cocktail. Ann NYAS, 962:207-11.
40. Estévez A, Sahawneh MA, Lange PS, et al. 2006. Arginase 1 regulation of nitric oxide production is key to survival of trophic factor-deprived motor neurons. J Neurosci, 26:8512-6.
41. Faden AI, Knoblach SM, Movsesyan VA, et al. 2004. Novel small peptides with neuroprotective and nootropic properties. J Alzheimer Dis, 6:S93-S97.
42. Famulski KE, MacDonald D, Paterson MC, et al. 1999. Activation of low pH-dependent nuclease by apoptotic agents. Cell Death Differ, 6:281-9.
43. Farrag TY, Lehar M, Verhaegen P, et al. 2007. Effect of platelet rich plasma and fibrin sealant on facial nerve regeneration in a rat model. Laryngoscope, 117:157-65.
44. Fedi P, Tronick SR, Aaronson SA. 1997. Growth factors. In: Holland JF, Bast RC, Morton DL, et al. (eds). Cancer Medicine. Baltimore: Williams and Wilkins, pp. 47-74.
45. Fernández-Vizarra P, Fernández AP. Castro-Blanco S, et al. 2004. Expression of nitric oxide system in clinically evaluated cases of Alzheimer disease. Neurobiol Dis, 15:287-305.
46. Furlong IJ, Ascaso R, Lopez Rivas A, et al. 1997. Intracellular acidification induces apoptosis by stimulating ICE-like protease activity. J Cell Sci, 110:653-61.
47. Gottlieb RA, Giesing HA, Zhu JY, et al. 1995. Cell acidification and apoptosis: granulocyte colony-stimulating factor delays programmed cell death by up-regulating the vacuolar ATPase. Proc Natl Acad Sci U S A, 92:5965-8.
48. Gottlieb RA, Nordberg J, Skowronski E, et al. 1996. Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci U S A, 93:654-8.
49. + exchange and growth factor-induced cytosolic changes. Role in cellular proliferation. Biochem Biophys Acta, 988:73-97.
50. Guo Q, Sopher BJ, Furukawa K, et al. 1997. Alzheimer presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and β-amiloid peptide: involvement of calcium and oxyradicals. J Neurosci, 17:4212-22.
51. Hamilton G, Cosentini EP, Teleky B, et al. 1993. The multidrug-resistance modifiers verapamil, cyclosporine A and tamoxifen induce an intracellular acidification in colon carcinoma cell lines in vitro. Anticancer Res, 13(6A):2059-63.
52. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell, 100:57-70.
53. + antiporter inhibitors as a novel approach to cancer treatment. In Cragoe EJ Jr, Kleyman ThR, Simchowitz L (eds). Amiloride and its analogs: unique cation transport inhibitors. New York: VCH Publishers Inc, pp. 317-34.
54. Harguindey S. 2002. Integrating fields of cancer research through pivotal mechanisms and synthetic final pathways: A unifying and creative overview. Med Hypotheses, 58:444-52; Erratum. 2003. Med Hypotheses, 61:318-19.
55. + antiporter in oncology in the light of the spontaneous regression of cancer and cell metabolism, Med Hypotheses, 39:229-37.
56. +-mediated unifying approach: pH-related and pH-unrelated mechanisms. Critical Rev Oncog, 6:1-33.
57. + exchanger: induction mechanisms and treatment implications. Apoptosis, 5:87-9.
58. + antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin-one single nature. Bioch Biopyhs Acta Revs Cancer, 1756:1-24.
59. + exchanger in Alzheimer's disease, other neurodegenerative diseases and cancer: new therapeutic possibilities and potential dangers. Curr Alzheimer Res, 4:53-65.
60. Harguindey S, Orive G, Anitua E, et al. 2008. Hacia un nuevo enfoque integrado del tratamiento de las enfermedades neurodegenerativas (ENDs): de etiopatogenia a tratamiento. El síndrome de deficiencia de factores tróficos y de crecimiento (SDFC). Gen T, 3:82-9.
61. Hefti F. 1983. Alzheimer's disease caused by a lack of nerve growth factor? Ann Neurol, 13:109-10.
62. Hirakura Y, Lin M-Ch, Kagan BL. 1999. Alzheimer amyloid aβ1-42 channels: effect of solvent, pH, and congo red. J Neurosci Res, 57:458-66.
63. Hirpara J, Clément M-V, Pervaiz S. 2001. Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells. J Biol Chem, 276:514-21.
64. Ishaque A, Al-Rubeai M. 1998. Use of intracellular pH and annexin V flow cytometric assays to monitor apoptosis and its suppression by bcl-2 over-expression in hybridoma cell culture. J Immunol Methods, 221:43-57.
65. Izumi HT, Torigoe T, Ishiguchi H, et al. 2003. Cellular pH regulators: potentially promising molecular targets of cancer chemotherapy. Cancer Treat Rev, 29:541-9.
66. Jin K, Zhu Y, Sun Y, et al. 2002. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA, 99:11946-50.
67. Kerr JF, Wyllie AH, Currie AR. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 26:239-57.
68. Khaled AR, Moor AN, Li A, et al. 2001. Thropic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalinization. Mol Cell Biol, 21:7545-57.
69. Kirkland RA, Franklin JI. 2003. Prooxidant effects of NGF withdrawal and MEK inhibition in sympathetic neurones. Antioxid Redox Signal, 5:635-9.
70. Kut C, Mac Gabhann F, Popel S. 2007. Where is VEGfin the body? A meta-analysis of EGF distribution in cancer. Br J Cancer, 97:978-85.
71. Lagadic-Gossmann D, Huc L, Lecureur V. 2004. Alterations of intracellular pH homeostasis in apoptosis: origins and roles. Cell Death Differ, 11:953-61.
72. + antiport abolishes growth factor-induced DNA synthesis in fibroblasts. J Biol Chem, 259:4313-9.
73. Lavrik IN, Golks A, Krammer PH. 2005. Caspases: pharmacological manipulation of cell death. J Clin Invest, 115:2665-72.
74. Lambrechts D, Storkebaum E, Morimoto M, et al. 2003. VEGF is a modifier of amyothropic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet, 34:357-8.
75. Letai AG. 2008. Diagnosing and exploiting cancer's addition to blocks in apoptosis. Nature Revs Cancer, 8:121-32.
76. +)-antiport. J Biol Chem, 270:3203-11.
77. Lieberthal W, Triaca V, Koh JS, et al. 1998. Role of superoxide in apoptosis induced by growth factor withdrawal. Am J Physiol, 275:F691-F702.
78. Liu D, Martino G, Thangaraju M, et al. 2000. Caspase-8-mediated intracellular acidification preceds mitochondrial dysfunction in somatostatin-induced apoptosis. J Biol Chem, 275:9244-50.
79. Marches R, Vitetta ES, Uhr JW. 2001. A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas. Proc Natl Acad Sci USA, 98:3434-9.
80. Mateo I, Llorca I, Infante J, et al. 2007. Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand, 116:56-8.
81. Matsuyama S, Llopis J, Deveraux QL, et al. 2000. Changes in intramitchondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nature Cell Biol, 2:318-25.
82. Matsuyama S, Reed JC. 2000. Mitochondria-dependent apoptosis and cellular pH regulation. 2000. Cell Death Differ, 7:1155-65.
83. McCarthy MJ, Rubin LL, Philott KL. 1997. Involvement of caspases in sympathetic neuron apoptosis. J Cell Sci, 110:2165-73.
84. Meléndez Hevia E. 2001. Natural selection and thermodynamics in biological evolution: from the origin of life to cancer. Servicio de Publicaciones de la Universidad de La Laguna, Tenerife, Spain. pp. 1-88.
85. + exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer, 115:924-9.
86. + exchange and cytoplasmatic pH in the action of growth factors in human fibroblasts. Nature, 304:645-8.
87. + antiporter in cancer angiogenesis and antiangiogenesis. Br J Cancer, 89:395-9.
88. + exchange inhibitor on neuronal cell death and brain ischemia. Brain Res, 1061:67-71.
89. Pérez-Sala D, Collado-Escobar D, Mollinedo F. 1995. Intracellular alkalinization supresses lovastatin-induced apoptosis in HL60 cells through the inactivation of a pH-dependent endonuclease. J Biol Chem, 270:6235-42.
90. Mishra, A. Pavelko, T. 2007. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med, 34:1774-8.
91. Murray MM, Spindler KP, Abreu E, et al. 2007. Collagen-platelet rich plasma hydrogel enhances primary repair of the porcine anterior cruciate ligament. J Orthop Res, 25:81-91.
92. Pang I-H, Zeng H, Fleenor D, et al. 2007. Pigment epithelium-derived factor protects retinal ganglion cells. BMC Neurosci, 8:1-11.
93. Park HJ, Lyons JC, Ohtsubo, et al. 1999. Acidic environment causes apoptosis by increasing caspase activity. Br J Cancer, 80:1892-7.
94. Perona R, Sánchez-Pérez I. 2007. Signalling pathways involved in clinical responses to chemotherapy. Clin Transl Oncol, 9:625-33.
95. Politi LE, Rotstein NP, Salvador G, et al. 2001. Insulin-like growth factor- I is a potential trophic factor for amacrine cells. J Neurochem, 76:1199-211.
96. Poser S, Impey S, Xia Z et al. 2003. Brain-derived neurotrophic factor protection of cortical neurones from serum withdrawal-induced apoptosis is inhibited by cAMP. J Neurosci, 23:4420-7.
97. Poüysségur J, Dayan F, Mazure NM. 2006. Hypoxia signalling in cancer and approaches to enforce tumor regression. Nature, 441:437-43.
98. Prodan CI, Ross ED, Vincent AS, et al. 2007. Coated-platelets correlate with disease progression in Alzheimer's disease. J Neurol, 254:548-9.
99. Raina AK, Zhu X, Rottkamp CA, et al. 2000. Cyclin' towards dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer's disease. J Neurosci Res, 61:128-33.
100. Raina AK, Hochman A, Ickes H, et al. 2003. Apoptotic promoters and inhibitors in Alzheimer's disease: who wins out? Prog Neuropsychopharmacol Biol Psych, 27:251-4.
101. Ray S, Britschgi M, Herbert CH, et al. 2007. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Med, 13:1359-62.
102. Rebollo A, Gómez J, de Aragón AM, et al. 1995. Apoptosis induced by IL-2 withdrawal is associated with an intracellular acidification. Exp Cell Res, 218:581-5.
103. Reed JC. 2002. Apoptosis-based therapies. Nat Revs Drug Discov, 1:111-21.
104. Reed JC. 2004. Apoptosis mechanisms: Implications for cancer drug discovery. Oncology, 18:11-20.
105. Renz A, Berdel WE, Kreuter M, et al. 2001. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood, 98:1542-8.
106. + exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J, 14:2185-97.
107. + Exchanger (NHE) Isoform 1 in Human Breast cancer cells. Clinical Cancer Res, 9:2366-73.
108. Resnick L, Fennell M. 2004. Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Disc Today, 9:932-9.
109. Reynolds JE, Li JF, Craig RW, et al. 1996. BCL-2 and MCL-1 expression in chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Exp Cell Res, 225:430-6.
110. + exchanger. Blood, 95:1427-34.
111. Rideout HJ, Stefanis L. 2001. Caspase inhibition: a potential strategy in neurological diseases. Histol Histopathol, 6:895-908.
112. Riedl AJ, Shi Y. 2004. Molecular mechanisms of caspase regulation during apoptosis. Nature Revs Mol Cell Biol, 5:897-907.
113. Rigas B, Sun Y. 2008. Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br J Cancer, 98:1157-60.
114. Riva M, Molteni R, Bedogni F, et al. 2005. Emerging role of the FGF system in psychiatric disorders. Trends Pharmacol Sci, 26:228-31.
115. i homeostasis in multidrug-resistant (MDR) cells: further characterization ora series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry, 32:11042-56.
116. Roepe PD. 2001. pH and multidrug resistance, In: Gillies RG (ed). The tumor microenvironment: causes and consequences of hypoxia and acidity. Novartis Foundation Symposium, No. 240. Chichester, New York: John Wiley and Sons Ltd., pp. 232-47.
117. Sajadi A, Bensadoun J-Ch, Schneider BL, et al. 2006. Transient striatal delivery of GNDF via encapsulated cells to sustained behavioral improvement in a bilateral model of Parkinson's disease. Neurobiol Dis, 22:119-29.
118. Schulte-Herbrüggen O, Jockers-Scherübi MC, Hellweg R. 2008. Neurotropins: from physiopathology to treatment of Alzheimers's disease. Curr Alz Res, 5:38-44.
119. Shacka JJ, Roth KA. 2005. Regulation of neural cell death and neurodegeneration by members of the Bel-2 family: therapeutic implications. Curr Drug Targets CNS Neurol Dis, 4:25-39.
120. Sehgal I, Powers S, Huntley B, et al. 1994. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA, 91:4673-7.
121. Simon S. 2001. The multiple mechanisms of drug resistance and cellular pH. In: Gillies R (ed). The tumor microenvironment: causes and consequences of hypoxia and acidity. Novartis Foundation Symposium No. 240. Chichester, New York: John Wiley and Sons, Ltd., pp. 269-81.
122. Slevin JT, Gash DM, Smith CD, et al. 2006. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson's disease: response to 1 year each of treatment and withdrawal. Neurosurg Focus, 20:E1.
123. Solerte SB, Ferrari E, Cuzzoni G, et al. 2005. Decrease release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulphate. Dement Geriatr Cogn Disord, 19:1-10.
124. Sortwell CE, Bowers WJ, Counts SE, et al. 2007. Effect of ex vivo transduction of mesencephalic reagggregates with bcl-2 on grafted dopamine neuron survival. Brain Res, 1134:33-4.
125. Sperandio S, de Belle I, Bredesen DE. 2000. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci U S A, 97:14376-81.
126. Storkebaum E, Carmeliet P. 2004a. VEGF: a critical player in neurodegeneration. J Clin Invest, 113:14-18.
127. Storkebaum E, Lambrechts D, Dewerchin M, et al. 2004b. Treatment of motoneuron degeneration by intraventricular delivery of VEGF in a rat model of ALS. Nature Neurosci, 8:85-92.
128. Szakács G, Paterson JK, Ludwig JA, et al. 2006. Targeting multidrug resistance in cancer. Nature Revs, 5:219-31.
129. Tafani M, Cohn JA, Karpinich NO, et al. 2003. Regulation of intracellular pH mediates Bax activation in HeLa cells treated with staurosporine on tumor necrosis factor-alpha. J Biol Chem, 277:49569-76.
130. Taetle R, Dos Santos B, Ohsuigi Y, et al. 1994. Effect of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma. J Natl Cancer Inst, 86:450-5.
131. Takashaki A, Masuda, Sun M, et al. 2004. Oxidative stress-induced apoptosis is associated with alterations in mitochondrial caspase activity and Bcl-2-dependent alterations in mitochondrial pH (pHm). Brain Res Bull, 62:497-504.
132. Tang DG, Li L, Chopra DP, et al. 1998. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res, 58:3466-79.
133. Tatton WG, Chamblers-Redman R, Ju WJH, et al. 2002. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharm Exp Therap, 301:753-64.
134. Tatton W, Chen D, Chamblers-Redman R, et al. 2003. Hypotheses for a common basis for neuroprotection in glaucoma and Alzheimer's disease: antiapoptosis by alpha-2-adrenergic receptor activation. Survey Ophtalmol, 48(Suppl 1):s25-s37.
135. Thangaraju M, Sharma K, Leber B, et al. 1999. Regulation of acidification and apoptosis by SHP-1 and BCL-2. J Biol Chem, 274:29549-57.
136. Thompson CB, Bauer DE, Lum JJ, et al. 2005. How do cancer cells acquire the fuel needed to support cell growth? Cold Spring Harbor Symp Quant Biol, 70:357-62.
137. +-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs, 13.237-43.
138. Troy CM, Stefanis L, Prochiantz A, et al. 1996. The contrasting roles of ICE family proteases and inteleukin-1β in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc Natl Acad Sci U S A, 93:5635-40.
139. Vaghefi H, Hughes Al, Neet KE. 2004. Nerve growth factor withdrawal-mediated apoptosis in naïve and differentiated PC12 cells through p53/caspase-3-dependent and -independent pathways. J Biol Chem, 279:15604-14.
140. Varon S. Manthorpe M, Williams LR. 1983. Neuronotrophic and neurite-promoting factors and their clinical potentials. Dev Neurosci, 6:73-86.
141. Vende Velde Ch, Cleveland DW. 2005. VEGF: multitasking in ALS. Nature Neurosci, 8:5-7.
142. Vincent AM, TenBroecke M, Maiese K. 1999. Neuronal intracellular pH directly mediates nitric oxide-induced programmed cell death. J Neurobiol, 40:171-84.
143. Wagner B, Natajaran A, Grünaug S, et al. 2006. Neuronal survival depends on EGFR signalling in cortical but not in midbrain astrocytes. EMBO J, 25:752-62.
144. Wahl ML, Owen JA, Burd R, et al. 2002. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Therap, 1:617-28.
145. Waibel M, Kramer S, Lauder K, et al. 2007. Mitochondria are not required for death-receptor mediated cytosolic acidificaction during apoptosis. Apoptosis, 12:623-30.
146. Waldeimer PC, Tatton W. 2004. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? Drug Discover Today, 9:210-8.
147. Waldeimer PC. 2003. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharm Biol Psychiatry, 27:303-21.
148. Wallace, JL, Dicay M, McKnight W, et al. 2006. Platelets accelerate gastric ulcer healing through presentation of vascular endothelial growth factor. Br J Pharmacol, 148:274-8.
149. Wilkins A, Nikodemova M, Compston A, et al. 2004. Minocycline attenuates nitric oxide-mediated neuronal axonal destruction in vitro. Neuron Glia Biol, 1:297-305.
150. Williams ACT, Collard J, Paraskeva C. 1999. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene, 18:3199-204.
151. Yan CY, Ferrari G, Greene LA. 1995. N-acetylcysteine-promotes survival of PC12 cells is gluthation-independent but transcription-dependent. Am Soc Biochem Mol Biol, 270:26827-32.
152. Yang SP, Bae AG, Kang HJ, et al. 2004. Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging, 25:283-90.
153. Yang J, Xuesong Liu, Kapil Bhalla, et al. 1997. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science, 75:1129-32.
154. Yang S-P, Dong-Goo Bae, Kang H J, et al. 2004. Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging, 25:283-90.
155. Zanke BW, Lee C, Arab S, et al. 1998. Death of tumor cells after intracellular acidification is dependent on stress-activated protein kinases (SAPK/JNK) pathway activation and can not be inhibited by Bcl-2 expression or inteleukin β-converting enzyme inhibition, Cancer Res, 58:2801-8.
156. Zhiuha X, Schendel S, Matsuyama S, et al. 1998. Acidic pH promotes dimerization of Bcl-2 family proteins. Biochemistry, 37:6410-18.
157. Zhu JK, Sun Y, Mao XO, et al. 2002. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA, 99:11946-50.
158. Zhu X, Ogawa O, Wang Y, et al. 2003. JKK1, an upstream activator of JNK/ SAPK, is activated in Alzheimer's disease. J Neurochem, 85:87-93.
159. Zubenko GS, Cohen BM, Reynolds CF. 1987a. Platelet membrane fluidity in Alzheimer's disease and major depression. Am J Psychiatry, 144:860-8.
160. Zubenko GS, Wusylko M, Cohen BM, et al. 1987b. Family study of platelet membrane fluidity in Alzheimer's disease. Science, 238:539-42.